Where to buy Tesamorelin Peptide: sizes, price per mg and how to verify the lot

What "tesamorelin peptide" names, and what it does not

Tesamorelin is the full 44-residue human GHRH sequence, amidated at the C-terminus, with one addition: a trans-3-hexenoyl group on the N-terminal tyrosine that protects the chain from the enzyme that clips native GHRH. Theratechnologies developed it under the code TH9507; formula C221H366N72O67S, average mass 5,135.9 Da, supplied as the acetate. Listings write tesamorelin, tesamorelin acetate, tesamorelin peptide and TH9507. It is the longest GHRH-family peptide in the catalogue, fifteen residues longer than sermorelin and Mod GRF, and correspondingly more expensive to make and to characterise.

An approved medicine, Egrifta, contains tesamorelin. The research vial is not that product. Egrifta is manufactured under an approval to a specification and released against it; a research vial is a synthetic peptide with the same sequence sold as laboratory material and standing on its lot certificate. No equivalence is claimed here and none is possible from a certificate, which measures a lot and not a manufacturing process. Sellers who write "same as Egrifta" are borrowing a reputation the powder has not earned.

Chemically the points that matter to a buyer are the hexenoyl group and the methionine. The hexenoyl adds 96 Da to the bare GHRH(1-44) amide, so a lot without it, which is cheaper to make, weighs 5,040 Da and is a different compound. The methionine at position 27 oxidises, adding 16 Da, and a 44-mer has several asparagine and glutamine residues that deamidate. The clinical papers cited below describe the drug; this page describes the material, not any use.

The reference point for identity is public. PubChem lists Tesamorelin as CID 16137828 with molecular formula C221H366N72O67S, an average molecular weight of 5136 Da and a monoisotopic mass of 5132.717 Da. Those are the numbers a mass spectrometer is checked against, and the number a certificate must print beside the observed mass.

In plain terms: A man-made copy of growth-hormone-releasing hormone (GHRH). What is sold here is a research chemical, not a drug product. Listing it is not an approval and not a claim that it is equivalent to or a fit substitute for any medicine.

Tesamorelin for sale: sizes and price per mg

LabFirst lists Tesamorelin in 3 sizes (5mg, 10mg, 20mg) from $45 to $150, priced per vial with the per-mg figure beside it so sizes can be compared without arithmetic. Per mg, the 20mg vial is the cheapest at $7.50 and the 5mg the dearest at $9, which is the usual shape: the vial, stopper, seal, fill and laboratory run cost the same whatever mass goes in.

The volume tiers are per size, not per basket: ten vials of one size take 10% off that line and twenty take 15%, and mixed sizes do not combine. Shipping is a flat $15 on orders under $200 and free from $200, within the United States only, with same-day dispatch on orders placed before 12 PM Pacific on a business day. The cost per mg tool runs the same comparison across any two listings, ours or anyone else's.

Forty-four residues plus an N-terminal acylation is a long, expensive synthesis with a demanding purification, and tesamorelin is priced accordingly; it is the dearest GHRH-family peptide per milligram in the catalogue. The per-milligram figure falls across the 5, 10 and 20 mg vials for the usual reason, the vial, the fill and the laboratory run being fixed costs spread over more mass. A laboratory qualifying a lot buys the 5 mg vial once and reads its certificate for the hexenoyl mass and the sulfoxide peak before buying larger.

The price trap is the des-hexenoyl peptide. GHRH(1-44) amide without the hexenoyl group is cheaper to make and 96 Da lighter, and it appears under the tesamorelin name at prices that look like a discount. The observed mass on the certificate is the only defence. The only discounts on this page are the volume tiers, per size and unchanged month to month, and the lot on the vial is whatever the certificate index says on the day.

The certificate a Tesamorelin lot must carry

Three tests answer three different questions, and a certificate of analysis for Tesamorelin is only complete when it carries all three for the exact lot on the vial. Identity is settled by mass spectrometry, and the number to look for on a Tesamorelin certificate is 5132.717 Da monoisotopic (or 5136 Da average, if the laboratory reports the deconvoluted average mass). The observed mass should sit within the instrument's stated tolerance of that figure, and the certificate should print both the theoretical and the observed value, not just a tick.

Purity is a separate question, answered by HPLC: how much of what came off the column was the compound. The figure is only interpretable with its method beside it (column, gradient, detection wavelength) and a date, which is what ICH Q2(R2) means when it asks that an analytical procedure be shown fit for its purpose. A percentage with no method and no date is a number somebody typed, and a certificate that carries every test but for a different lot number than the vial is the most common failure of all and the easiest to catch. Net content is the third test and the one most often missing: the milligrams of Tesamorelin actually in the vial, measured, against the size printed on the label.

Identity is the deconvoluted mass against 5,135.9 Da average (about 5,132.7 Da monoisotopic), with the certificate saying which it reports. The electrospray envelope runs from about 4+ to 8+ (m/z 1,285, 1,028, 857, 735 and so on) and a laboratory that prints it beside the deconvoluted value has shown its work. Two wrong answers are worth knowing: about 5,040 Da is GHRH(1-44) amide without the hexenoyl group, a different and cheaper peptide; a mass 16 Da high is the methionine sulfoxide, which as a small named peak is honest ageing and as the main peak is a degraded lot.

Purity by HPLC on a 44-mer is a resolution problem: the des-hexenoyl form, the sulfoxide, deamidated forms and truncated sequences all elute near the main peak, so the chromatogram with its column, gradient and wavelength is the evidence and the percentage only its summary. Net content is the line that pays on a peptide this expensive: quantitative HPLC against a standard or amino acid analysis tells you how many of the labelled milligrams are peptide rather than acetate, trifluoroacetate and water, and on a 20 mg vial the gap is routinely a fifth of the price. The counter-ion belongs beside that figure.

Where to buy Tesamorelin: five checks before you order from anyone

Every seller of tesamorelin peptide says "third-party tested". The phrase costs nothing. These five checks take about four minutes per listing and separate a tested lot from a tested-sounding one.

1. The lot on the vial is the lot on the certificate. Read the printed lot number, then open the certificate and match it. A certificate for "Tesamorelin" with no lot, or a lot that does not match, describes some other vial.
2. The laboratory is named and has its own lookup. The report should come from a laboratory the seller does not own, with a search code you can enter on the laboratory's own site. LabFirst lots are tested by Freedom Diagnostics and looked up by accession number; anything that can only be verified on the seller's own page has not been verified.
3. The theoretical mass is printed, and it is the right one. For Tesamorelin that is 5132.717 Da monoisotopic; a certificate that prints a different figure has either measured a different molecule or copied a template.
4. Purity has a method and a date. An HPLC percentage should name the method and the run date. A figure that reads "99%+" with neither, or one date reused across every product a seller lists, is decoration.
5. Net content is stated in milligrams. The label size is a claim; the certificate's net content is the measurement. If the certificate has no net content line, the purity figure describes the powder, not the vial, and the price per mg you calculated is fiction.

How listings for Tesamorelin specifically mislead:

• "Same as Egrifta" or "pharmaceutical grade". Egrifta is an approved product with a release specification; a research vial has a lot certificate and nothing else, and no equivalence is claimed or possible.
• A price far below the market for a 44-residue acylated peptide. The cheap version is usually GHRH(1-44) amide without the hexenoyl group, 96 Da lighter on the certificate and a different compound.
• A certificate with one rounded mass and no spectrum. A 5,136 Da molecule gives a charge-state envelope that must be deconvoluted; a bare number with no trace could describe anything.
• "99.9%" with no sulfoxide or deamidation peaks named. A 44-mer with a methionine ages in known ways; a certificate that never sees those peaks may never have looked.

How to verify a LabFirst Tesamorelin lot

The Tesamorelin sizes in stock today carry lots LF-2608-28 and PO-1001-TSM10 and PO-1001-TSM20. Lot LF-2608-28 is at Freedom Diagnostics on accession FD-2026-05716 for identity, purity and net content. Until the report is attached the product page says "pending verification" against that lot and makes no purity claim; the price stands and the report goes live the day it arrives, on the page, at /coa/, and inside the receipt and packing slip for every order of that lot.

Verification runs through the laboratory, not through us. Open the certificate index, find the lot, and use the accession number on the Freedom Diagnostics lookup page; the report you see there is the laboratory's copy, not ours. Each lot also carries a Finnrick verify link, and every receipt and packing slip states that a customer may submit a sealed vial to Finnrick's free testing programme with the order as proof of purchase, so the brand's public record is built from vials we did not choose.

The product page reads the live stock feed on load (stock, lot and certificate state for every size), so what you see when you order is what ships. The lot is printed on the label and encoded in the QR patch on its right-hand side; scanning it opens that lot's record.

Storage and shipping for Tesamorelin

Lyophilised and sealed at 2 to 8 C out of light, tesamorelin holds for the shelf period on the certificate. Its weaknesses are named residues: methionine 27 oxidises in air and light, several asparagines and glutamines deamidate in solution, and the tryptophan makes light exposure matter once dissolved; all three are slow in the dry cake and fast in solution, so a prepared solution is dated, kept cold, protected from light and used inside the laboratory's own stability record rather than any figure on a label. The sealed cake's other enemy is water drawn from humid air once the vial is opened: open a vial once, for its purpose, and never re-seal one for storage.

Orders ship within the United States, flat $15 under $200 and free above it, same day when placed before 12 PM Pacific on a business day, and the shipping page states the cutoff, the carriers and what is and is not promised.

The record a laboratory keeps on arrival is what makes the certificate usable later, and it is short:

• the lot number as printed on the vial, and the certificate's accession or search code beside it;
• the date received and the condition of the seal;
• the storage location and temperature it went into;
• the number of vials, and later the date each one was opened and by whom.

A Tesamorelin vial with that record behind it can be traced from the bench to the laboratory report in one step; without it, the certificate is a document about a vial that can no longer be identified.

Regulatory status, and what this page is not

Tesamorelin is the active ingredient of an approved medicine, Egrifta (2010), from Theratechnologies. That approval belongs to that product and its manufacturing and confers nothing on a research vial: the material sold here is not made under it, is not tested to its specification and is offered as laboratory material only, with no claim that it is equivalent to, as pure as, or a substitute for any medicine. There is no USP monograph for the bulk peptide that a research lot could claim to meet, and the existence of an approved product is, if anything, a reason to read the lot certificate more carefully, since it is the only evidence a research vial has.

FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. LabFirst sells Tesamorelin to laboratories and researchers as material for in-vitro work, gives no guidance on use, and ships only against that understanding. Nothing on this page or on the product page describes preparing or administering anything.

What is Tesamorelin studied for?

Published research on Tesamorelin investigates the areas below — which is a different question from what Tesamorelin will do for anyone, a claim about a living system that nothing on this site is sold for.

What it is. A man-made copy of growth-hormone-releasing hormone (GHRH).

What the research looks at. There is a registered clinical record, and an approved medicine containing tesamorelin exists under its own brand name for one specific condition.

How it is thought to work. It works on the GHRH receptor. It is a hardier copy of the hormone that triggers growth hormone, rather than growth hormone itself, which matters: it acts one step earlier in the chain.

What is not established. What is sold here is a research chemical, not a drug product. Listing it is not an approval and not a claim that it is equivalent to or a fit substitute for any medicine.

The full record, including the certificate for the lot in stock, is on the Tesamorelin product page.

Common questions

Sources

• PubChem, Tesamorelin, CID 16137828. Public record for the molecular formula (C221H366N72O67S), average molecular weight (5136 Da) and monoisotopic mass (5132.717 Da) quoted here as the identity reference.
• Stanley and colleagues, Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial, JAMA 2014. Primary description of the compound in the literature; supports the class and naming stated here, not any use.
• Friedman and colleagues, Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging, JAMA Neurology 2013. Primary description of the compound in the literature; supports the class and naming stated here, not any use.
• ICH Q2(R2), Validation of Analytical Procedures (2023) 2023-11. Why a purity figure is only interpretable with its method, and what "fit for purpose" means for the HPLC and mass spectrometry results a certificate reports.
• Freedom Diagnostics, certificate lookup by accession number. The laboratory-side lookup a LabFirst lot is verified on; the report there is the laboratory copy, not ours.
• Finnrick, verify a vendor or lot. Independent verification page linked from every LabFirst lot; customers may submit sealed vials with their order as proof of purchase.